The global oncolytic virus CDMO services market is gaining significant momentum as pharmaceutical and biotechnology companies increasingly outsource the development and manufacturing of complex viral therapies.
According to Fortune Business Insights, the global oncolytic virus CDMO services market size was valued at USD 634.6 million in 2025. The market is projected to grow from USD 715.4 million in 2026 to USD 2,169.5 million by 2034, exhibiting a CAGR of 14.9% during the forecast period.
Oncolytic viruses are emerging as an important approach in cancer treatment because they can selectively target and destroy tumor cells while stimulating the body's immune response. As research pipelines expand and more candidates progress toward clinical development and commercialization, pharmaceutical companies are increasingly relying on contract development and manufacturing organizations (CDMOs) with specialized capabilities in viral vector production, process development, analytical testing, and GMP manufacturing.
The rising number of oncology-focused biotechnology programs is one of the major factors driving demand for oncolytic virus CDMO services. Developing and manufacturing viral therapies requires specialized infrastructure, technical expertise, quality systems, and regulatory capabilities. Establishing these capabilities internally can require substantial capital investment and operational resources.
CDMOs provide biotechnology and pharmaceutical companies with access to established manufacturing platforms and specialized expertise without requiring them to build complete production facilities. This allows developers to focus on drug discovery, clinical development, and commercialization while outsourcing complex manufacturing activities.
The increasing complexity of advanced therapies is also encouraging companies to work with specialized service providers. CDMOs can support activities ranging from early-stage process development and analytical testing to clinical-scale manufacturing and commercial production.
North America dominated the oncolytic virus CDMO services market with a market share of 36.07% in 2025. The region's leadership is supported by its established biotechnology ecosystem, strong pharmaceutical industry, advanced healthcare infrastructure, and significant investment in cancer research and innovative therapies.
The U.S. represents a major center for the development of oncolytic virus therapies, with numerous biotechnology companies and research organizations advancing novel candidates through preclinical and clinical stages. The presence of experienced CDMOs further strengthens the region's position by providing specialized manufacturing and development capabilities.
Europe is also an important market, supported by growing investments in advanced therapies, regulatory expertise, and the presence of established pharmaceutical manufacturing organizations. Meanwhile, Asia Pacific is expected to present attractive opportunities as biotechnology capabilities and investments in advanced therapeutic manufacturing continue to expand.
Get Free Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/oncolytic-virus-cdmo-services-market-119065
Oncolytic virus CDMO providers offer a broad range of services designed to support pharmaceutical and biotechnology companies throughout the development lifecycle. These services may include process development, cell line and virus production, upstream and downstream processing, formulation development, analytical testing, quality control, and GMP manufacturing.
Clinical-stage companies particularly benefit from outsourcing because CDMOs can provide scalable manufacturing capabilities as programs progress from early development toward clinical trials. Specialized providers can also help companies address technical and regulatory requirements associated with viral products.
The ability to scale production efficiently is becoming increasingly important as promising oncolytic virus candidates advance through clinical development. Manufacturing partners with experience in viral technologies can help reduce development timelines and support consistent product quality.
The growing focus on precision oncology and immuno-oncology is creating new opportunities for oncolytic virus therapies. Unlike conventional cancer treatments that primarily target tumor cells through cytotoxic mechanisms, oncolytic viruses can combine direct tumor-cell destruction with immune-system activation.
This therapeutic potential is encouraging pharmaceutical and biotechnology companies to invest in research and development programs. As the number of candidates entering clinical development increases, demand
Explore Japan’s Market Opportunities - Latest- Oncolytic Virus CDMO Services Market - Insights